GlassScriptPhysician profile
Tarique D Perera
NPI 1730195751
$382,631.66
in general payments reported to CMS, 2019-2025
40 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $16K · 2021: $12K · 2022: $50K · 2023: $108K · 2024: $70K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Consulting Fee: $53K · Travel and Lodging: $29K · Food and Beverage: $15K · Honoraria: $8,775 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,400.00 |
| Consulting Fee | $53,309.25 |
| Travel and Lodging | $29,153.46 |
| Food and Beverage | $15,409.13 |
| Honoraria | $8,775.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $84,067.13 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $81,718.75 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $79,129.33 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $48,383.53 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41,277.23 | 2024-2025 | Cobenfy |
| Allergan, INC. | $20,858.12 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,390.91 | 2019-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $5,669.90 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $2,915.55 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $1,378.84 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $1,283.53 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,169.07 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $897.85 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Bausch Health US, LLC | $895.63 | 2019-2025 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $895.37 | 2022-2025 | Qelbree, Qelbree |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $771.05 | 2019-2022 | |
| Lundbeck LLC | $637.07 | 2019-2025 | Rexulti |
| Corium, LLC | $514.84 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $507.23 | 2019-2025 | Fanapt, Hetlioz |
| Arbor Pharmaceuticals, INC. | $360.57 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $317.76 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $193.16 | 2024-2025 | Rejoyn |
| Adlon Therapeutics L.P. | $126.09 | 2019-2021 | |
| Tempus Ai, INC | $120.33 | 2024 | |
| Tris Pharma INC | $116.29 | 2024-2025 | Dyanavel Xr |
| Shire North American Group INC | $115.71 | 2019 | |
| Idorsia Pharmaceuticals US INC | $107.85 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $106.27 | 2021-2023 | Jornay Pm |
| Neos Therapeutics, LP | $104.73 | 2019-2024 | Adzenys Xr-Odt |
| Eisai INC. | $97.78 | 2020-2021 | |
| Biogen, INC. | $94.01 | 2024-2025 | Zurzuvae |
| Almatica Pharma LLC | $92.01 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Harmony Biosciences LLC | $65.73 | 2020 | |
| Novo Nordisk INC | $51.46 | 2019 | |
| Merck Sharp & Dohme LLC | $48.78 | 2019 | |
| Glaxosmithkline, LLC. | $48.35 | 2022-2023 | Trelegy Ellipta |
| Vertical Pharmaceuticals, LLC | $38.53 | 2024-2025 | Relexxii |
| Azurity Pharmaceuticals, INC. | $24.77 | 2023 | Horizant |
| Collegium Pharmaceutical, INC. | $22.47 | 2025 | Jornay Pm |
| Lilly USA, LLC | $18.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarique Perera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.